These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28278708)

  • 41. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
    Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
    Haematologica; 2009 Dec; 94(12):1762-6. PubMed ID: 19797731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
    Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
    Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
    [No Abstract]   [Full Text] [Related]  

  • 43. Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
    Jann JC; Nowak D; Nolte F; Fey S; Nowak V; Obländer J; Pressler J; Palme I; Xanthopoulos C; Fabarius A; Platzbecker U; Giagounidis A; Götze K; Letsch A; Haase D; Schlenk R; Bug G; Lübbert M; Ganser A; Germing U; Haferlach C; Hofmann WK; Mossner M
    J Med Genet; 2017 Sep; 54(9):640-650. PubMed ID: 28600436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 45. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
    Ureshino H; Kizuka H; Kusaba K; Sano H; Nishioka A; Shindo T; Kubota Y; Ando T; Kojima K; Kimura S
    Int J Hematol; 2017 May; 105(5):692-696. PubMed ID: 27914067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5q-: pathogenetic importance of the common deleted region and clinical consequences of the entire deleted segment.
    Pedersen B
    Anticancer Res; 1993; 13(5C):1913-6. PubMed ID: 8267400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
    Kerdivel G; Chesnais V; Becht E; Toma A; Cagnard N; Dumont F; Rousseau A; Fenaux P; Chevret S; Chapuis N; Boeva V; Fridman WH; Fontenay M; Kosmider O
    Leukemia; 2018 Feb; 32(2):558-562. PubMed ID: 28972593
    [No Abstract]   [Full Text] [Related]  

  • 51. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
    Sockel K; Bornhaeuser M; Mischak-Weissinger E; Trenschel R; Wermke M; Unzicker C; Kobbe G; Finke J; Germing U; Mohr B; Greiner J; Beelen D; Thiede C; Ehninger G; Platzbecker U;
    Haematologica; 2012 Sep; 97(9):e34-5. PubMed ID: 22952334
    [No Abstract]   [Full Text] [Related]  

  • 52. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
    Almeida A; Fenaux P; Garcia-Manero G; Goldberg SL; Gröpper S; Jonasova A; Vey N; Castaneda C; Zhong J; Beach CL; Santini V
    Leuk Lymphoma; 2018 Sep; 59(9):2135-2143. PubMed ID: 29322849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
    Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Holtan SG; Pardanani A; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
    Leukemia; 2010 Jul; 24(7):1283-9. PubMed ID: 20485371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
    Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
    Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
    Sekeres MA; Swern AS; Fenaux P; Greenberg PL; Sanz GF; Bennett JM; Dreyfus F; List AF; Li JS; Sugrue MM
    Blood Cancer J; 2014 Aug; 4(8):e242. PubMed ID: 25171203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.